The role of TLR4 and RSV F protein in immunity to RSV
TLR4和RSV F蛋白在RSV免疫中的作用
基本信息
- 批准号:8473654
- 负责人:
- 金额:$ 49.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-01-01 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:1 year oldAdjuvantAgonistAlveolar MacrophagesAlveolitisAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAntigensBindingBronchiolitisBronchopulmonary DysplasiaCD14 geneCXCL10 geneCase SeriesCell surfaceCellsCessation of lifeChildClinical TrialsComplexComputer AnalysisContractsCotton RatsCoupledDNADNA-Binding ProteinsDataDetectionDevelopmentDiseaseElderlyEmployee StrikesEngineeringEnzymesExhibitsFailureFamilyFormalinFrequenciesFundingGene Expression ProfileGenesGenetic PolymorphismGenetic TranscriptionGenotypeGoalsGram-Negative BacteriaGrantHistopathologyHospitalizationIL8 geneImmuneImmune responseImmunityImmunologic Deficiency SyndromesIn VitroInfantInfectionInflammation MediatorsInflammatoryInflammatory ResponseInterferonsInterleukin-12Interleukin-6InterventionLaboratoriesLeadLifeLigandsLipopolysaccharidesLungLymphocyte Antigen 96MediatingMembraneModelingMolecularMolecular ConformationMolecular GeneticsMonoclonal AntibodiesMorbidity - disease rateMusOutcomePalivizumabPathologicPathologyPathway interactionsPatternPattern recognition receptorPhasePlayPneumoniaPositioning AttributeProductionProstaglandinsProtein SubunitsProteinsRecombinantsRecruitment ActivityReportingResolutionRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesRespiratory SystemRespiratory syncytial virusRespiratory syncytial virus RSV F proteinsRespiratory tract structureRiskRoleSTAT1 geneSamplingSigmodonSignal PathwaySignal TransductionSignaling MoleculeSingle Nucleotide PolymorphismStructureSubunit VaccinesSurfaceTNF geneTestingTherapeuticTherapeutic InterventionToll-like receptorsVaccinatedVaccinationVaccinesVirus Diseasesagedairway hyperresponsivenessanalogautocrinebasechemokinecongenital heart disordercyclooxygenase 2cytokinehigh risk infanthuman IRF3 proteinhuman NOS2A proteinhuman TLR4 proteinimmunosuppressedin vivoinnovationinterferon regulatory factor-3killingslung injurymacrophagemicrobialmonophosphoryl lipid Amortalitynovelnovel therapeuticsparacrinepathogenprematureprophylacticprotein activationprototypereceptor expressionresponsesecondary infectiontherapeutic targettoll-like receptor 4transcription factorvolunteer
项目摘要
The respiratory tract is a major portal for pathogens. The bronchoalveolar macrophage, positioned at
the mucosal surface, recognizes "pathogen associated molecular patterns (PAMPs)" through "pattern
recognition receptors (PRRs)." A family of mammalian PRRs, "Toll-like receptors" (TLRs), are
transmembrane signaling molecules that respond to diverse PAMPs. Gram negative lipopolysaccharide
(LPS) stimulates cells through TLR4 to elicit a strongly proinflammatory pattern of gene expression, resulting
in a "Th1-type" cytokine milieu. Respiratory syncytial virus (RSV) is the leading cause of pneumonia and
bronchiolitis in infants and young children worldwide, and has recently been attributed to increased morbidity
and mortality in the elderly and immunosuppressed. The RSV fusion (F) protein is also a TLR4 agonist.
Prophylactic administration of anti-F antibodies to high-risk infants is highly protective. In a failed clinical trial
in the 1960's, a formalin-inactivated RSV (FI-RSV) vaccine led to exacerbated RSV disease, findings we
have recapitulated in the cotton rat (S. hispidus), assessed by pulmonary histopathology and airway
hyperreactivity. During the first cycle of this grant, we identified cyclooxygenase-2 and prostanoids as key
therapeutic targets for RSV-induced lung pathology. We found that vaccination of cotton rats with the original
FI-RSV used in the failed trials, newly formulated with a non-toxic adjuvant and TLR4 agonist,
monophosphoryl lipid A (MPL), suppressed FI-RSV vaccine-enhanced disease by blunting the mixed Th1-
and Th2-type "cytokine storm" that is elicited upon RSV infection of vaccinated subjects. In vitro, purified F
protein activation of NF-¿B and IL-8 secretion in HEK293T cells is TLR4-, MD-2-, and CD14-dependent, and
transfectants that express TLR4 proteins with one or both of two single nucleotide polymorphisms (SNPs),
previously associated with LPS-hyporesponsiveness, were significantly less responsive to purified RSV F
protein, under conditions of equal TLR expression. Importantly, we identified a highly significant
overrepresentation of these TLR4 SNPs in DNA samples derived from a case series of high-risk infants and
children with documented RSV infection. These data strongly support our overarching hypothesis that
TLR4 plays a central role in the innate immune response to RSV and imply that initial engagement of
TLR4 is required for development of a protective, adaptive immune response, rather than a pathological one.
This proposal details innovative experimental approaches that will (i) lead to development a safe and
effective RSV F protein subunit vaccine, (ii) lead to development of therapeutic intervention strategies based
on a characterization of the interaction of F protein with the TLR4/MD-2/CD14 complex and examine the
role(s) of TLR4 signaling in RSV infection/protection. It is expected that at the completion of this grant, we
will have identified strategies that may lead to development of a RSV vaccine and new therapeutics for
mitigating the pathologic host response to RSV.
呼吸道是病原体的主要门户。支气管肺泡巨噬细胞位于
粘膜表面,通过“模式识别”病原体相关分子模式(PAMP)
识别受体 (PRR)。”哺乳动物 PRR 家族“Toll 样受体”(TLR) 是
响应不同 PAMP 的跨膜信号分子。革兰氏阴性脂多糖
(LPS) 通过 TLR4 刺激细胞,引发强烈的促炎基因表达模式,从而产生
在“Th1型”细胞因子环境中。呼吸道合胞病毒(RSV)是引起肺炎和肺炎的主要原因
全世界婴儿和幼儿中的细支气管炎,最近被归因于发病率增加
以及老年人和免疫抑制者的死亡率。 RSV 融合 (F) 蛋白也是 TLR4 激动剂。
对高危婴儿预防性施用抗 F 抗体具有高度保护作用。在一次失败的临床试验中
在 20 世纪 60 年代,福尔马林灭活 RSV (FI-RSV) 疫苗导致 RSV 疾病加剧,我们发现
通过肺组织病理学和气道评估,在棉鼠(S. hispidus)中进行了重述
过度反应。在本次资助的第一个周期中,我们确定环氧合酶 2 和前列腺素类药物是关键
RSV 引起的肺部病理学的治疗靶点。我们发现用原疫苗接种棉鼠
失败试验中使用的FI-RSV,采用无毒佐剂和TLR4激动剂新配制,
单磷酰脂质 A (MPL),通过削弱混合 Th1- 抑制 FI-RSV 疫苗增强的疾病
接种疫苗的受试者感染 RSV 后引发的 Th2 型“细胞因子风暴”。体外纯化的 F
HEK293T 细胞中 NF-¿B 和 IL-8 分泌的蛋白激活是 TLR4-、MD-2- 和 CD14 依赖性的,并且
表达具有两个单核苷酸多态性(SNP)之一或两者的TLR4蛋白的转染子,
以前与 LPS 反应性低下相关,对纯化的 RSV F 的反应明显较低
蛋白质,在 TLR 表达相等的条件下。重要的是,我们发现了一个非常重要的
来自高危婴儿病例系列的 DNA 样本中这些 TLR4 SNP 的比例过高
有记录的 RSV 感染儿童。这些数据有力地支持了我们的总体假设:
TLR4 在 RSV 的先天免疫反应中发挥着核心作用,这意味着 TLR4 的初始参与
TLR4 是保护性、适应性免疫反应(而非病理性免疫反应)发展所必需的。
该提案详细介绍了创新的实验方法,这些方法将(i)导致开发安全且
有效的 RSV F 蛋白亚单位疫苗,(ii) 导致基于的治疗干预策略的开发
表征 F 蛋白与 TLR4/MD-2/CD14 复合物的相互作用,并检查
TLR4 信号传导在 RSV 感染/保护中的作用。预计在完成这笔赠款后,我们
将确定可能导致 RSV 疫苗和新疗法开发的策略
减轻宿主对 RSV 的病理反应。
项目成果
期刊论文数量(19)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.
- DOI:10.1089/jir.2009.0025
- 发表时间:2010-04
- 期刊:
- 影响因子:0
- 作者:Boukhvalova MS;Sotomayor TB;Point RC;Pletneva LM;Prince GA;Blanco JC
- 通讯作者:Blanco JC
Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology.
- DOI:10.1038/mi.2013.71
- 发表时间:2014-05
- 期刊:
- 影响因子:8
- 作者:
- 通讯作者:
Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.
- DOI:10.1128/mbio.00218-12
- 发表时间:2012
- 期刊:
- 影响因子:6.4
- 作者:Rallabhandi P;Phillips RL;Boukhvalova MS;Pletneva LM;Shirey KA;Gioannini TL;Weiss JP;Chow JC;Hawkins LD;Vogel SN;Blanco JC
- 通讯作者:Blanco JC
New insights for development of a safe and protective RSV vaccine.
- DOI:10.4161/hv.6.6.11562
- 发表时间:2010-06
- 期刊:
- 影响因子:0
- 作者:Blanco JC;Boukhvalova MS;Shirey KA;Prince GA;Vogel SN
- 通讯作者:Vogel SN
Modeling Human Respiratory Viral Infections in the Cotton Rat (Sigmodon hispidus).
- DOI:10.4172/jaa.1000093
- 发表时间:2014-03-03
- 期刊:
- 影响因子:0
- 作者:Blanco JC;Boukhvalova MS;Perez DR;Vogel SN;Kajon A
- 通讯作者:Kajon A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JORGE C BLANCO其他文献
JORGE C BLANCO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JORGE C BLANCO', 18)}}的其他基金
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 49.56万 - 项目类别:
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
RSV 诱导的 M2 巨噬细胞分化:TLR4/PPARg/RXR 信号轴的作用 (80)
- 批准号:
10418803 - 财政年份:2021
- 资助金额:
$ 49.56万 - 项目类别:
RSV-induced M2 macrophage differentiation: role of TLR4/PPARg/RXR signaling axis (80)
RSV 诱导的 M2 巨噬细胞分化:TLR4/PPARg/RXR 信号轴的作用 (80)
- 批准号:
10287155 - 财政年份:2021
- 资助金额:
$ 49.56万 - 项目类别:
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury
靶向 TLR 信号通路以减弱病原体介导的急性肺损伤
- 批准号:
9306674 - 财政年份:2017
- 资助金额:
$ 49.56万 - 项目类别:
Targeting TLR Signaling Pathways to Blunt Pathogen-mediated Acute Lung Injury
靶向 TLR 信号通路以减弱病原体介导的急性肺损伤
- 批准号:
10098763 - 财政年份:2017
- 资助金额:
$ 49.56万 - 项目类别:
Eritoran (E5564), a TLR4 antagonist, as a novel therapeutic for influenza
Eritoran (E5564),一种 TLR4 拮抗剂,作为流感的新型治疗剂
- 批准号:
8884533 - 财政年份:2013
- 资助金额:
$ 49.56万 - 项目类别:
相似海外基金
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 49.56万 - 项目类别:
Augmenting the Quality and Duration of the Immune Response with a Novel TLR2 Agonist-Aluminum Combination Adjuvant
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10499193 - 财政年份:2021
- 资助金额:
$ 49.56万 - 项目类别:
A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine
一种基于 TLR5 激动剂的新型脊髓灰质炎病毒疫苗佐剂
- 批准号:
9305008 - 财政年份:2016
- 资助金额:
$ 49.56万 - 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
- 批准号:
8054408 - 财政年份:2010
- 资助金额:
$ 49.56万 - 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
- 批准号:
7909550 - 财政年份:2010
- 资助金额:
$ 49.56万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
8126073 - 财政年份:2010
- 资助金额:
$ 49.56万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
7899536 - 财政年份:2009
- 资助金额:
$ 49.56万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7362543 - 财政年份:2007
- 资助金额:
$ 49.56万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7502193 - 财政年份:2007
- 资助金额:
$ 49.56万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7911043 - 财政年份:2007
- 资助金额:
$ 49.56万 - 项目类别:














{{item.name}}会员




